Nimotop (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This blockade causes vasodilation of intracranial vessels, improving cerebral perfusion and counteracting the constrictive response that leads to vasospasm following a subarachnoid bleed.

The specific dose of Nimotop is determined by the prescribing clinician based on the patient’s condition, weight, and renal or hepatic function. Healthcare professionals follow local guidelines and adjust the regimen according to individual therapeutic response and tolerability.

Safety data for nimodipine in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss individual risk factors with the patient before prescribing.

To request Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nimotop (nimodipine) is a dihydropyridine calcium‑channel blocker specifically approved for cerebral vasospasm prophylaxis, whereas other agents such as clazosentan target endothelin receptors. Nimodipine’s advantage lies in its selective cerebral vasodilatory effect with a well‑established safety profile in the context of subarachnoid hemorrhage.

Nimotop should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight.

Nimotop is administered orally, typically as a tablet taken with water. The exact dosing schedule and duration are prescribed by the treating physician, who will consider the patient’s clinical status and any concomitant medications.

The most serious risks include severe hypotension, which can lead to syncope or shock, and rare cardiac events such as myocardial infarction. Hepatic dysfunction and severe allergic reactions, though uncommon, also require immediate medical attention.

Patients with known hypersensitivity to nimodipine or other dihydropyridine calcium‑channel blockers should avoid Nimotop. Caution is also advised for individuals with uncontrolled hypotension, severe hepatic impairment, or those taking interacting medications that could precipitate dangerous blood‑pressure drops.